Cell Therapeutics (CTIC) Announces Pixantrone Now Available in Europe on a Named-Patient Basis
More News related to CTIC
- Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group
- Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45%
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Trading Review for Cell Therapeutics Incorporated Issued by Beacon Equity
- Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 5
More News related to Corporate News
- Odyssey Marine (OMEX) Acquires Minority Stake in SMM Project LLC
- NASDAQ Grants Comstock Homebuilding (CHCI) Continued Listing Request
- Agilysys (AGYS) Announces Special Meeting of Shareholders to Vote on Proposed Control Share Acquisition by MAK Capital
- Highlights From SJM's Q2 Conference Call: Acquisition of Folger's Really Paying Off; Comfortable Raising FY Outlook
- Pfizer (PFE) Gets Okay for Bipolar Treatment Geodon from U.S. FDA
Cell Therapeutics, Inc. (Nasdaq: CTIC) today announced that pixantrone is now available on a named-patient basis in Europe. Pixantrone will be supplied by IDIS to healthcare professionals for the treatment of individual patients with aggressive non-Hodgkin's lymphoma that has either relapsed after standard therapies or is refractory to them. We know of no therapy that has previously been shown to be effective treatment for such patients.
A named-patient program is a compassionate use drug supply program under which physicians can legally supply investigational drugs to qualifying patients. Under a named-patient program, investigational drugs can be administered to patients who are suffering from serious illnesses prior to the drug being approved by the European Medicines Evaluation Agency. "Named-patient" distribution refers to the distribution or sale of a product to a specific healthcare professional for the treatment of an individual patient. In Europe, under the named-patient program the drug is most often purchased through the national health system.
Related Categories
Corporate NewsStocks Mentioned
-0.03Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
It's not over yet
Roy P on May 5, 2009 11:12 PMMy wife and I held onto CTIC for quite some time, believing in them. As a cancer survivor, this was one stock I knew I could believe in. Their successes aren't over yet. Just wait until their meds are approved by the FDA and released in the US. By the way - from what I understand, they still have two more meds on their way to the public as well.